// App-Quantinova.ai

: An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials

Researchers

Presenter

  • P. Conaghan

Principal Investigators

  • V. Strand

  • D. Hunter

  • V.B. Kraus

  • F. Berenbaum

  • N.P. Katz

  • J. Lufkin

  • J.R. Johnson

  • S. Kelley

  • N. Bodick

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Stanford Univ., Portola Valley, CA, USA

  • University of NSW, Sydney, Australia

  • Duke Univ. Sch. of Med., Durham, NC, USA

  • Pierre and Marie Curie University, Paris, France

  • Analgesic Solutions, Tufts Univ. Sch. of Med., Natick, Boston, MA, USA

  • Flexion Therapeutics, Inc., Burlington, MA, USA,

Locations

  • United Kingdom

  • United States

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Knee osteoarthritis

  • Spondylocostal dysostosis 5

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Triamcinolone acetonide

  • FX006

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved